<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222585</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00024571</org_study_id>
    <secondary_id>HHSN27500003I</secondary_id>
    <nct_id>NCT01222585</nct_id>
  </id_info>
  <brief_title>Metronidazole Pharmacokinetics (PK) in Premature Infants</brief_title>
  <acronym>PTN_METRO</acronym>
  <official_title>Safety and Pharmacokinetics of Multiple Dose Metronidazole in Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Cohen-Wolkowiez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Yearly in the United States over 500,000 newborns are delivered prematurely. This population
      is at high risk of catastrophic bowel disease known as necrotizing enterocolitis. Infants
      with necrotizing enterocolitis are at high risk of death, and survivors are at increased risk
      of mental retardation. Metronidazole is an antibiotic that is often administered to infants
      with suspected or confirmed necrotizing enterocolitis. Unfortunately, the appropriate dose of
      metronidazole in premature infants has not been established and it is likely to be different
      from older children and adults.

      The investigators will investigate the appropriate metronidazole dose in very premature
      infants by: 1) determining how premature infants eliminate metronidazole from the body and 2)
      determining the safest and most effective dose of metronidazole in premature infants.

      The investigators hypothesis are: 1) The rate of removal of metronidazole will increase with
      infant maturity and 2) an appropriate metronidazole dosing regimen will result in necessary
      drug levels to treat bacteria involved in necrotizing enterocolitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve at Steady State</measure>
    <time_frame>pre-dose: 30 min; post-dose:10 min, 3-4,6-8, 12-13, 24-25, 36-37, 48-49, 72-73 hours post dose</time_frame>
    <description>Area under the curve at steady state (AUCss)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Loading Dose Maximum Concentration</measure>
    <time_frame>2-5 days of study drug administration</time_frame>
    <description>Loading Dose Maximum concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Loading Dose Minimum Concentration</measure>
    <time_frame>2-5 days of study drug administration</time_frame>
    <description>Loading Dose Minimum Concentration (mg/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Maximum Concentration</measure>
    <time_frame>2-5 days of study drug administration</time_frame>
    <description>Multiple Dose Maximum Concentration (mg/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Minimum Concentration</measure>
    <time_frame>2-5 days of study drug administration</time_frame>
    <description>Multiple Dose Minimum Concentration (mg/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance</measure>
    <time_frame>2-5 days of study drug administration</time_frame>
    <description>Clearance (L/h/kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution</measure>
    <time_frame>2-5 days of study drug administration</time_frame>
    <description>Volume of Distribution (L/kg)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Serious Systemic Infections</condition>
  <condition>Necrotizing Enterocolitis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with &gt;=14 postnatal days and every 24 hours for infants &lt;14 postnatal days.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age &lt;32 weeks at the time of enrollment.

          -  Postnatal age &lt;91 days at the time of enrollment.

          -  Sufficient venous access to permit administration of study medication.

          -  Infant suspected to have a serious infection and from whom a blood culture has been
             obtained within 96 hours of study entry.

        Exclusion Criteria:

          -  History of anaphylaxis to metronidazole or other nitroimidazole derivatives (e.g.,
             tinidazole).

          -  Previous exposure to metronidazole in the week prior to study.

          -  Previous participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Cohen-wolkowiez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHOC Children's</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesely Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cohen-Wolkowiez M, Sampson M, Bloom BT, Arrieta A, Wynn JL, Martz K, Harper B, Kearns GL, Capparelli EV, Siegel D, Benjamin DK Jr, Smith PB; Best Pharmaceuticals for Children Actâ€“Pediatric Trials Network. Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J. 2013 Sep;32(9):956-61. doi: 10.1097/INF.0b013e3182947cf8.</citation>
    <PMID>23587979</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <results_first_submitted>July 23, 2013</results_first_submitted>
  <results_first_submitted_qc>October 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 18, 2013</results_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Michael Cohen-Wolkowiez</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Metronidazole</keyword>
  <keyword>Neonate</keyword>
  <keyword>Premature</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Necrotizing enterocolitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metronidazole IV</title>
          <description>Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Post Natal Age (Days)</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="1" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Gestational age (weeks)</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="23" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth Weight</title>
          <units>grams</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="740" lower_limit="431" upper_limit="1466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve at Steady State</title>
        <description>Area under the curve at steady state (AUCss)</description>
        <time_frame>pre-dose: 30 min; post-dose:10 min, 3-4,6-8, 12-13, 24-25, 36-37, 48-49, 72-73 hours post dose</time_frame>
        <population>The PK analysis was conducted using samples from 23 subjects. One subject died soon after the loading dose and was excluded from the analysis. Two subjects had no multiple dose samples. Thus data from 20 subjects were used to estimate this PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole IV</title>
            <description>Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve at Steady State</title>
          <description>Area under the curve at steady state (AUCss)</description>
          <population>The PK analysis was conducted using samples from 23 subjects. One subject died soon after the loading dose and was excluded from the analysis. Two subjects had no multiple dose samples. Thus data from 20 subjects were used to estimate this PK parameter.</population>
          <units>mg*hr/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.0" lower_limit="66.0" upper_limit="472.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Loading Dose Maximum Concentration</title>
        <description>Loading Dose Maximum concentration (Cmax)</description>
        <time_frame>2-5 days of study drug administration</time_frame>
        <population>The sample size contains the number of subjects that had the sample of interest collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole IV</title>
            <description>Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Loading Dose Maximum Concentration</title>
          <description>Loading Dose Maximum concentration (Cmax)</description>
          <population>The sample size contains the number of subjects that had the sample of interest collected.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.54" lower_limit="9.18" upper_limit="19.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Loading Dose Minimum Concentration</title>
        <description>Loading Dose Minimum Concentration (mg/L)</description>
        <time_frame>2-5 days of study drug administration</time_frame>
        <population>The sample size contains the number of subjects that had the sample of interest collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole IV</title>
            <description>Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Loading Dose Minimum Concentration</title>
          <description>Loading Dose Minimum Concentration (mg/L)</description>
          <population>The sample size contains the number of subjects that had the sample of interest collected.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.20" lower_limit="3.21" upper_limit="12.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Maximum Concentration</title>
        <description>Multiple Dose Maximum Concentration (mg/L)</description>
        <time_frame>2-5 days of study drug administration</time_frame>
        <population>The PK analysis was conducted using samples from 23 subjects. One subject died soon after the loading dose and was excluded from the analysis. Two subjects had no multiple dose samples. Thus data from 20 subjects were used to estimate the multiple dose PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole IV</title>
            <description>Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Maximum Concentration</title>
          <description>Multiple Dose Maximum Concentration (mg/L)</description>
          <population>The PK analysis was conducted using samples from 23 subjects. One subject died soon after the loading dose and was excluded from the analysis. Two subjects had no multiple dose samples. Thus data from 20 subjects were used to estimate the multiple dose PK parameter.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.51" lower_limit="8.71" upper_limit="34.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Minimum Concentration</title>
        <description>Multiple Dose Minimum Concentration (mg/L)</description>
        <time_frame>2-5 days of study drug administration</time_frame>
        <population>The sample size contains the number of subjects that had the sample of interest collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole IV</title>
            <description>Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Minimum Concentration</title>
          <description>Multiple Dose Minimum Concentration (mg/L)</description>
          <population>The sample size contains the number of subjects that had the sample of interest collected.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.62" lower_limit="1.29" upper_limit="27.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clearance</title>
        <description>Clearance (L/h/kg)</description>
        <time_frame>2-5 days of study drug administration</time_frame>
        <population>The PK analysis was conducted using samples from 23 subjects. One subject died soon after the loading dose and was excluded from the analysis. Two subjects had no multiple dose samples. Thus data from 20 subjects were used to estimate the PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole IV</title>
            <description>Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance</title>
          <description>Clearance (L/h/kg)</description>
          <population>The PK analysis was conducted using samples from 23 subjects. One subject died soon after the loading dose and was excluded from the analysis. Two subjects had no multiple dose samples. Thus data from 20 subjects were used to estimate the PK parameter.</population>
          <units>L/h/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.043" lower_limit="0.016" upper_limit="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution</title>
        <description>Volume of Distribution (L/kg)</description>
        <time_frame>2-5 days of study drug administration</time_frame>
        <population>The PK analysis was conducted using samples from 23 subjects. One subject died soon after the loading dose and was excluded from the analysis. Two subjects had no multiple dose samples. Thus data from 20 subjects were used to estimate the PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole IV</title>
            <description>Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution</title>
          <description>Volume of Distribution (L/kg)</description>
          <population>The PK analysis was conducted using samples from 23 subjects. One subject died soon after the loading dose and was excluded from the analysis. Two subjects had no multiple dose samples. Thus data from 20 subjects were used to estimate the PK parameter.</population>
          <units>L/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.38" upper_limit="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose through 10 days post dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Necrotising colitis</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septic shock</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Patent ductus arteriosus repair</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders Adrenal Insufficiency</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other non-serious, infrequent adverse events</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Cohen-Wolkowiez, MD</name_or_title>
      <organization>Duke Clinical Research Institute</organization>
      <phone>919668-8812</phone>
      <email>michael.cohenwolkowiez@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

